Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H32N4O4.H2O |
| Molecular Weight | 434.5292 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.OC(=O)C[C@H](NC(=O)[C@@H]1CCCN(C1)C(=O)CCC2CCNCC2)C3=CC=CN=C3
InChI
InChIKey=VHTVZWUXMIOMAD-VOMIJIAVSA-N
InChI=1S/C22H32N4O4.H2O/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17;/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29);1H2/t18-,19+;/m1./s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H32N4O4 |
| Molecular Weight | 416.5139 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11672755Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17115723 | http://adisinsight.springer.com/drugs/800010575
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11672755
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17115723 | http://adisinsight.springer.com/drugs/800010575
Elarofiban is a novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist. It inhibits thrombin-induced platelet aggregation in human gel-filtered platelets and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, arachidonic acid, ADP, and SFLLRN-NH(2). Elarofiban had adequate oral pharmacokinetics in dogs and excellent oral pharmacodynamics. Elarofiban has been in phase II clinical trials for the treatment of myocardial infarction and thrombosis. However, this research has been discontinued.
Originator
Sources: http://www.google.ch/patents/US6069254
Curator's Comment: the subsidiary of Johnson & Johnson
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. | 2017-07 |
|
| Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. | 2002-08-08 |
|
| Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. | 2001-10-15 |
|
| 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. | 2001-10-08 |
|
| Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. | 1999-12-16 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17115723
Oral: 3 mg/kg
Intravenous: 0.03 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17115723
Elarofiban inhibited platelet aggregation in human platelet-rich plasma in response to multiple agonists (collagen, ADP, TRAP-6, arachidonic acid; IC50 = 60-160 nM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:49 GMT 2025
by
admin
on
Mon Mar 31 18:29:49 GMT 2025
|
| Record UNII |
6Y891C0JEV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29750
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
216231
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
C72753
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
LL-72
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
6Y891C0JEV
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
221005-96-5
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL87728
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
DTXSID70944740
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY | |||
|
C402922
Created by
admin on Mon Mar 31 18:29:49 GMT 2025 , Edited by admin on Mon Mar 31 18:29:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |